In a filing, Monopar Therapeutics Inc revealed its Chief Financial Officer Radhakrishnan Karthik acquired Company’s shares for reported $25188.0 on Oct 28 ’24. In the deal valued at $16.25 per share,1,550 shares were bought. As a result of this transaction, Radhakrishnan Karthik now holds 1,550 shares worth roughly $44237.0.
Then, Cittadine Andrew bought 20,508 shares, generating $15,254 in total proceeds. Upon buying the shares at $0.74, the Chief Operating Officer now owns 186,132 shares.
Before that, Cittadine Andrew bought 12,000 shares. Monopar Therapeutics Inc shares valued at $10,320 were divested by the Chief Operating Officer at a price of $0.86 per share. As a result of the transaction, Cittadine Andrew now holds 165,624 shares, worth roughly $4.73 million.
Piper Sandler initiated its Monopar Therapeutics Inc [MNPR] rating to an Overweight in a research note published on January 10, 2025; the price target was $72. A number of analysts have revised their coverage, including Rodman & Renshaw’s analysts, who began to cover the stock in mid October with a ‘”a Buy”‘ rating. ROTH Capital began covering MNPR with “Buy” recommendation on January 28, 2021.
Price Performance Review of MNPR
On Friday, Monopar Therapeutics Inc [NASDAQ:MNPR] saw its stock fall -6.36% to $28.54. Over the last five days, the stock has gained 12.58%. Monopar Therapeutics Inc shares have risen nearly 29.73% since the year began. Nevertheless, the stocks have risen 1203.20% over the past one year. While a 52-week high of $38.50 was reached on 01/17/25, a 52-week low of $1.54 was recorded on 01/03/25. SMA at 50 days reached $22.45, while 200 days put it at $8.92.
Levels Of Support And Resistance For MNPR Stock
The 24-hour chart illustrates a support level at 26.15, which if violated will result in even more drops to 23.77. On the upside, there is a resistance level at 31.44. A further resistance level may holdings at 34.34. The Relative Strength Index (RSI) on the 14-day chart is 60.16, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 3.59, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 31.15%. Stochastics %K at 85.17% indicates the stock is a selling.
How much short interest is there in Monopar Therapeutics Inc?
A steep rise in short interest was recorded in Monopar Therapeutics Inc stocks on 2024-10-15, dropping by -0.6 million shares to a total of 49852.0 shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 0.65 million shares. There was a decline of -1208.86%, which implies that there is a negative sentiment for the stock.
